Skip to content
The Cancer History Project
HOME
ABOUT
THE CANCER HISTORY PROJECT
THE CANCER LETTER
EDITORIAL BOARD
SPONSORS
CONTRIBUTORS
TCL ARCHIVES
LATEST ARTICLES
Search for:
Search
ARCHIVES
FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.
This article is from
The Cancer Letter
archive.
Vol. 31 No. 02 | January 14, 2005
Download PDF
Visit The Full Archive
Related Articles
TCL Archive
FY 1984 Bypass Budget Shown By Mechanism,, Research Program
July 2, 1982
TCL Archive
Ovariectomy Without HRT Increases Death Rate
September 29, 2006
TCL Archive
RFA On Breast Tumor Factors Patients Survival
June 20, 1980
TCL Archive
Nexavar Improves PFS In Phase III Trial
January 25, 2013
TCL Archive
Advocacy: Journal Club Leader Sought By NBCC
August 22, 1997
TCL Archive
Studies of Oncotype DX Test Presented at ASCO Symposium
January 31, 2014